Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. It is not yet known if combination chemotherapy is more effective with or without
rituximab in treating mantle cell lymphoma.
PURPOSE: Randomized phase II trial to compare the effectiveness of fludarabine and
cyclophosphamide combined with rituximab to that of fludarabine and cyclophosphamide alone in
treating patients who have mantle cell lymphoma.